Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 23.4% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hypertonic sodium chloride solution increases plasma osmolality, drawing water from intracellular to extracellular space, expanding intravascular volume, and promoting diuresis. It also provides sodium and chloride ions for electrolyte replenishment.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Severe symptomatic hyponatremia (e.g., serum sodium <120 m Eq/L with neurological symptoms),Intracranial hypertension (osmotic diuresis to reduce cerebral edema)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Severe hyponatremia: 100-150 m L of 23.4% sodium chloride (27-40 g Na Cl) IV over 1-2 hours via central line; maximum rate 1-2 m L/min. Repeat dose based on serum sodium levels. Not for direct IV push; must be diluted or used via central line.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Not applicable as sodium chloride is an electrolyte; distribution and elimination follow body sodium homeostasis, with renal regulation having a half-life of hours to days depending on volume status.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Not metabolized; sodium and chloride ions are excreted primarily by the kidneys.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: >95% as sodium and chloride ions; negligible biliary/fecal.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
0%; not bound to plasma proteins.
Low protein binding; 0–11% bound, primarily to albumin.
0.6–0.7 L/kg; distributes into extracellular fluid.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Oral: 100% (passive absorption); IV: 100%.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No standard GFR-based dose adjustment; use caution in renal impairment due to risk of fluid overload and hypernatremia. Monitor serum electrolytes and volume status closely.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific Child-Pugh based adjustment; use with caution in cirrhosis with ascites due to fluid overload risk. Monitor sodium and volume.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Severe symptomatic hyponatremia: 0.5-1 m L/kg of 23.4% sodium chloride (115-230 mg Na Cl/kg) IV over 1-2 hours; maximum 100 m L. Administer via central line. Repeat based on serum sodium correction.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Use lowest effective dose; monitor for fluid overload, hypernatremia, and cardiac decompensation. Dose same as adult but adjust for renal function and comorbidities. Consider slower infusion rate.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Not FDA-approved for injection; extravasation causes severe tissue necrosis. Use extreme caution to avoid extravasation during administration.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of central pontine myelinolysis (osmotic demyelination) with rapid correction of hyponatremia,Extravasation hazard leading to tissue necrosis,May cause fluid overload, hypernatremia, and hyperchloremic metabolic acidosis,Use with caution in patients with heart failure, renal impairment, or edema
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypernatremia,Fluid overload states (e.g., pulmonary edema),Known hypersensitivity to sodium chloride
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Dietary restrictions typically involve avoiding high-sodium foods if concurrent salt supplementation is not needed. Patients with hyponatremia may need controlled sodium intake; follow specific dietary guidelines from your provider. Avoid excessive fluid intake as it may dilute sodium levels.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
No known teratogenic risk; sodium chloride is a normal blood constituent. However, hypernatremia from high doses may cause fetal dehydration. First trimester: no fetal risk. Second/third trimesters: monitor maternal serum sodium to avoid hypernatremia, which can cause fetal osmotic shifts.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Compatible with breastfeeding. Sodium chloride is normally present in breast milk; M/P ratio approximately 1.0. No adverse effects expected with usual doses.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No specific dose adjustment required. However, physiologic hypervolemia of pregnancy may necessitate careful monitoring to avoid fluid overload. Standard dosing based on individual electrolyte deficits and clinical status.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
23.4% sodium chloride is a hypertonic solution for severe hyponatremia or cerebral edema; administer via central line due to high osmolarity (8000 m Osm/L) to avoid phlebitis. Monitor serum sodium closely — correct at 4-6 m Eq/L over 24 hours to prevent osmotic demyelination. Use with extreme caution in heart failure, renal impairment, or hypovolemia. Do not mix with medications.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is a concentrated salt solution given through a large vein to increase sodium levels in your blood.,You will need frequent blood tests to monitor your sodium and other electrolyte levels.,You may experience headache, nausea, or swelling at the injection site; report these to your healthcare provider immediately.,Notify your doctor if you have a history of heart failure, kidney disease, or if you are on a low-salt diet.,Avoid drinking excessive amounts of water during treatment unless directed by your doctor.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 23.4% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE 23.4% is a Electrolyte that works by Hypertonic sodium chloride solution increases plasma osmolality, drawing water from intracellular to extracellular space, expanding intravascular volume, and promoting diuresis. It also provides sodium and chloride ions for electrolyte replenishment.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 23.4% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 23.4% is: Severe hyponatremia: 100-150 m L of 23.4% sodium chloride (27-40 g Na Cl) IV over 1-2 hours via central line; maximum rate 1-2 m L/min. Repeat dose based on serum sodium levels. Not for direct IV push; must be diluted or used via central line.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE 23.4% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 23.4% is classified as Category A/B. No known teratogenic risk; sodium chloride is a normal blood constituent. However, hypernatremia from high doses may cause fetal dehydration. First trimester: no fetal risk. Second. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.